MD

• Texas A&M University College of Medicine

• Internal Medicine Residency at University of Utah

• Fellowship in Rheumatology at University of Virginia

• Additional Training in Rheumatology at the University of Auckland in New Zealand

• Chair of the Illinois Chapter of the Association of Women in Rheumatology

• Serves on the Association of Women in Rheumatology Advocacy Committee

• Serves on the American College of Rheumatology State Council

Adjunct Faculty for the LaGrange Family Practice Residency

Dr. Crowley loves traveling and spending time with her family!

• A. Crowley, L. Siegel, H. Jones, D. Webster, E. Moon, T. He, L. Yang, J. Curtis, Bend Ease: A Novel App-Based Digital Measurement Tool for Assessing At-Home Morning Stiffness and Spinal Range of Motion in Axial Spondyloarthritis. Abstract, European League Against Rheumatism, Vienna Austria 2024

• Crowley AR, et al., The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 study.  Poster: American College of Rheumatology Convergence 2023

• Tubb AR, Liokis E, Alford B, Kimpel DL. Catching a break. The American Journal of Medicine. 121(5):357-456, 2008.

• Crowley AR, Dong J, Clarke A, McHaffie A, Reeves Q, Williams M, Robinson E, Dalbeth N, McQueen, F. Measuring bone erosion and edema in rheumatoid arthritis: a comparison of manual segmentation and RAMRIS methods. Journal of Magnetic Resonance Imaging. 33(2):364-71, Feb 2011. Peer Review: Ad hoc reviewer for: Journal of Rheumatology

• June 2024, Principal Investigator, UCB PA0016: A multicenter, randomized, double-blind, risankizumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult study participants with active psoriatic arthritis

• April 2024, Principal Investigator, Novartis CAIN457E22101: An open-label, multicenter study to evaluate the pharmacokinetics, safety and tolerability of intravenous secukinumab infusion in adults with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR)

• April 2024, Principal Investigator, Novartis CVAY736F12302: A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)

• April 2024, Principal Investigator, Horizon HZNP-KRY-409: A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks Compared with KRYSTEXXA Administered Every 2 Weeks with Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants with Uncontrolled Refractory Gout (FORWARD II)

• April 2024, Principal Investigator, Novartis CAIN457012302: A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy

• April 2024, Principal Investigator, Acelyrin 23110: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis

• April 2024, Principal Investigator, GSK 219240: A Phase 4, multicenter, prospective, open-label study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythematosus

• September 2023, Principal Investigator, Aqtual PRIMA 102: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with inadequate response or intolerance to bDMARD or tsDMARD +/- csDMARD Changing Treatment to a bDMARD or tsDMARD Treatment +/- csDMARD)

• June 2023, Principal Investigator, AbbVie M23-699: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE (SELECT-SLE), 

• June 2023, Principal Investigator, AbbVie M23-700: A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH), 

• May 2023, Principal Investigator, Setpoint RESET-RA SPM-020: Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study

• April 2023, Principal Investigator, Acelyrin 22014: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis,

• November 2022, Principal Investigator, Eli Lilly J1A-MC-KDAF: A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants with Moderately-to Severely Active Rheumatoid Arthritis

• February 2022, Principal Investigator, Janssen CNTO1959PSA4002: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease, (STAR) 

• May 2021, Principal Investigator, Amgen CC-10004-PSA-013: A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast in Subjects With Early, Oligoarticular, Moderately Active Psoriatic Arthritis Despite Initial Stable Treatment with Either NSAIDs or <1 Conventional Synthetic DMARD, (FOREMOST) 

• May 2021, Principal Investigator, CORRONA BIO-100 Biorepository

• March 2021, Principal Investigator, Sun Pharma TILD-19-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE I)

• July 2020, Principal Investigator, Eli Lilly I4V-MC-JAJD: A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA-Branch)

• April 2020, Principal Investigator, CORRONA RA-100 POWER: Patient Outcomes: Real World Evidence in Rheumatoid Arthritis (POWER), (patient experience with JAK inhibitors) 

• October 2019, Principal Investigator, AbbVie M16-011: A Phase 3 Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug Therapy (DMARD) (KEEPsAKE1) 

• October 2019, Principal Investigator, AbbVie M19-130: A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLEek), 

• April 2019, Principal Investigator, CorEvitas PSA/SpA: CorEvitas Psoriatic and Spondyloarthritis registry

• April 2019, Principal Investigator, CorEvitas RA: Consortium of Rheumatology Research in North America